Journals / Medicine Science / 2016 / Cilt: 5 - Sayı: 0

Current Treatment Approaches of Uterine Fibroids

Pages
174–183
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Such as the lack of risk associated with surgery, shorter time to return to normal life is advantages of interventional radiological methods.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myoma uteri are the most common benign uterine tumors among women of reproductive age .
📊
Key Findings & Data:These benign tumors are a public health problem worldwide.
💡
Conclusion & Impact:Such as the lack of risk associated with surgery, shorter time to return to normal life is advantages of interventional radiological methods.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Myoma uteri are the most common benign uterine tumors among women of reproductive age . These benign tumors are a public health problem worldwide. There are many options for the treatment of uterine myoma. Place in medical treatment of uterine myoma treatment is limited due to side effects and drug costs. Medical treatment is usually used temporary in the form of before surgery. Surgical treatment of uterine myoma should be individualized according to patient age, size and location of myoma. Treatment with interventional radiological methods of uterine myoma is not common for the moment. Such as the lack of risk associated with surgery, shorter time to return to normal life is advantages of interventional radiological methods.

🔖

Cite This Article

KEÇECİOĞLU, M. (2016). Current Treatment Approaches of Uterine Fibroids. Medicine Science, Cilt: 5 - Sayı: 0, 174–183. https://ajindex.com/articles/277745

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Fernandez H, Chabbert-Buffet N, Koskas M, Nazac A. Epidemiological data for uterine fibroids in France in 2010-2012 in medical center - analysis from the French DRG-based information system (PMSI). J Gynecol Obstet Biol Reprod (Paris). 2014;43(8):616-28. Parker WH. Uterine myomas: management. Fertil Steril 2007;88(2):255-71. American College of Obstetricians and Gynecologists. Alternatives to hysterectomy in the management of leiomyomas. ACOG Practice Bulletin No. 96. Obstet Gynecol. 2008;112(2 pt 1):387-400.
  2. Marret H, Fritel X, Ouldamer L, Bendifallah S, Brun JL, De Jesus I, Derrien J, Giraudet G, Kahn V, Koskas M, Legendre G, Lucot JP, Niro J, Panel P, Pelage JP, Fernandez H; CNGOF (French College of Gynecology and Obstetrics). Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol. 2012;165:156-64. Pérez-López FR, Ornat L, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Schenck-Gustafsson K, Simoncini T, Tremollieres F, Rees M. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106-16. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293-8.
  3. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol. 1994;83(4):566-72.
  4. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006;(2):CD003855. Qin J, Yang T, Kong F, Zhou Q. Oral contraceptive use and uterine leiomyoma risk: A meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet. 2013;288(1):139-48.
  5. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams- Campbell LL, Rosenberg L. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113-23.
  6. Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol. 2004; 24(7):798-800.
  7. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003;79(5):1194-8.
  8. Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regre